Abstract | PURPOSE: METHODS: Growth-inhibiting effects have been tested by the MTT and ATP viability assays. Apoptosis has been detected by the caspase-cleaved cytokeratin 18 (M30-antigen) assay. Necrosis has been detected by staining the cells with fluorescent dyes. Mitotic index has been calculated by counting the mitotic figures after staining with hematoxylin. RESULTS: The complex 3 exhibited significant anti-growth effects, and its anti-growth effect was more powerful than that of cisplatin that is a standard chemotherapeutic agent for this type of cancer. The complexes did not induce apoptosis, while necrosis clearly took place. CONCLUSIONS: Novel Pd(II) complex ([ PdCl(terpy)](sac)·2H(2)O) seems to represent a potentially active drug against non-small cell lung cancer cell lines, and further studies in vivo are warranted.
|
Authors | Engin Ulukaya, Ferda Ari, Konstantinos Dimas, Mehmet Sarimahmut, Emel Guney, Nikos Sakellaridis, Veysel T Yilmaz |
Journal | Journal of cancer research and clinical oncology
(J Cancer Res Clin Oncol)
Vol. 137
Issue 10
Pg. 1425-34
(Oct 2011)
ISSN: 1432-1335 [Electronic] Germany |
PMID | 21809029
(Publication Type: Journal Article)
|
Chemical References |
- Organometallic Compounds
- Organoplatinum Compounds
- Palladium
- Adenosine Triphosphate
- Cisplatin
|
Topics |
- Adenosine Triphosphate
(analysis)
- Apoptosis
(drug effects)
- Carcinoma, Non-Small-Cell Lung
(drug therapy, pathology)
- Cell Line, Tumor
- Cisplatin
(pharmacology)
- Humans
- Lung Neoplasms
(drug therapy, pathology)
- Mitosis
(drug effects)
- Necrosis
- Organometallic Compounds
(pharmacology)
- Organoplatinum Compounds
(pharmacology)
- Palladium
(pharmacology)
|